CY1122449T1 - Σχηματα δοσολογιας ανοσοσυζευγματος enanti-folr1 - Google Patents

Σχηματα δοσολογιας ανοσοσυζευγματος enanti-folr1

Info

Publication number
CY1122449T1
CY1122449T1 CY20191101260T CY191101260T CY1122449T1 CY 1122449 T1 CY1122449 T1 CY 1122449T1 CY 20191101260 T CY20191101260 T CY 20191101260T CY 191101260 T CY191101260 T CY 191101260T CY 1122449 T1 CY1122449 T1 CY 1122449T1
Authority
CY
Cyprus
Prior art keywords
enanti
immune conjugate
folr1
dosage schemes
folr1 immune
Prior art date
Application number
CY20191101260T
Other languages
Greek (el)
English (en)
Inventor
Robert J. Lutz
Jose Ponte
Original Assignee
Immunogen, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52813740&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1122449(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Immunogen, Inc. filed Critical Immunogen, Inc.
Publication of CY1122449T1 publication Critical patent/CY1122449T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Medicinal Preparation (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Botany (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CY20191101260T 2013-10-08 2019-12-02 Σχηματα δοσολογιας ανοσοσυζευγματος enanti-folr1 CY1122449T1 (el)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361888365P 2013-10-08 2013-10-08
US201361888337P 2013-10-08 2013-10-08
US201461948363P 2014-03-05 2014-03-05
US201462004815P 2014-05-29 2014-05-29
PCT/US2014/059716 WO2015054400A2 (en) 2013-10-08 2014-10-08 Anti-folr1 immunoconjugate dosing regimens

Publications (1)

Publication Number Publication Date
CY1122449T1 true CY1122449T1 (el) 2021-01-27

Family

ID=52813740

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20191101260T CY1122449T1 (el) 2013-10-08 2019-12-02 Σχηματα δοσολογιας ανοσοσυζευγματος enanti-folr1
CY20241100517T CY1127391T1 (el) 2013-10-08 2024-07-16 Σχηματα δοσολογιας ανοσοσυζευγματος εναντι- folr1

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20241100517T CY1127391T1 (el) 2013-10-08 2024-07-16 Σχηματα δοσολογιας ανοσοσυζευγματος εναντι- folr1

Country Status (29)

Country Link
US (3) US20150132323A1 (https=)
EP (3) EP3653228B1 (https=)
JP (5) JP6463744B2 (https=)
KR (7) KR20220136468A (https=)
CN (1) CN106164093A (https=)
AU (4) AU2014331964C1 (https=)
BR (1) BR112016007479A2 (https=)
CA (1) CA2926325C (https=)
CY (2) CY1122449T1 (https=)
DK (2) DK3055332T3 (https=)
ES (2) ES2759426T3 (https=)
FI (1) FI3653228T3 (https=)
HR (2) HRP20240917T1 (https=)
HU (2) HUE067367T2 (https=)
IL (4) IL298044B2 (https=)
LT (2) LT3653228T (https=)
MX (2) MX384973B (https=)
MY (1) MY174670A (https=)
NZ (2) NZ757964A (https=)
PL (2) PL3055332T3 (https=)
PT (2) PT3055332T (https=)
RS (2) RS65798B1 (https=)
RU (1) RU2696579C2 (https=)
SG (3) SG10201907042PA (https=)
SI (2) SI3653228T1 (https=)
SM (1) SMT201900694T1 (https=)
UA (1) UA119541C2 (https=)
WO (1) WO2015054400A2 (https=)
ZA (1) ZA201902009B (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI622402B (zh) 2010-02-24 2018-05-01 免疫遺傳股份有限公司 葉酸受體１抗體類和免疫共軛物類及彼等之用途
BR112013025415B1 (pt) * 2011-04-01 2021-03-16 Immunogen, Inc uso de um imunoconjugado antirreceptor de folato 1 (folr1)
US9200073B2 (en) 2012-08-31 2015-12-01 Immunogen, Inc. Diagnostic assays and kits for detection of folate receptor 1
SG11201509043RA (en) * 2013-05-14 2015-12-30 Immunogen Inc Anti-folr1 immunoconjugate dosing regimens
CN113150145B (zh) 2013-08-30 2025-02-14 伊缪诺金公司 用于检测叶酸受体1的抗体和测定
CN116440279B (zh) * 2015-09-17 2026-02-24 伊缪诺金公司 包含抗folr1免疫缀合物的治疗组合
US20180333503A1 (en) * 2017-05-16 2018-11-22 Immunogen, Inc. Anti-folr1 immunoconjugates and anti-pd-1 antibody combinations
KR20250035037A (ko) * 2017-09-18 2025-03-11 서트로 바이오파마, 인크. 항-엽산 수용체 알파 항체 접합체 및 이의 용도
AU2019236091B2 (en) 2018-03-13 2025-06-05 Phanes Therapeutics, Inc. Anti-folate receptor 1 antibodies and uses thereof
CN112955548B (zh) * 2018-07-09 2023-11-24 普众发现医药科技(上海)有限公司 叶酸受体α特异性抗体
MA55818A (fr) 2019-04-29 2022-03-16 Immunogen Inc Anticorps et immunoconjugués de fr-alpha biparatopique
EP4347661A4 (en) * 2021-06-04 2025-06-18 ImmunoGen, Inc. TREATMENT OF CANCER IN PATIENTS WITH SOLUBLE FR-ALPHA
AU2022402850A1 (en) * 2021-12-01 2024-06-06 Sutro Biopharma, Inc. Anti-folate receptor conjugate cancer therapy
US20250059274A1 (en) * 2021-12-24 2025-02-20 Bio-Thera Solutions, Ltd. ANTI-FRa ANTIBODY, AND ANTIBODY-DRUG CONJUGATE AND USE THEREOF

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3896111A (en) 1973-02-20 1975-07-22 Research Corp Ansa macrolides
US4307016A (en) 1978-03-24 1981-12-22 Takeda Chemical Industries, Ltd. Demethyl maytansinoids
US4256746A (en) 1978-11-14 1981-03-17 Takeda Chemical Industries Dechloromaytansinoids, their pharmaceutical compositions and method of use
JPS55102583A (en) 1979-01-31 1980-08-05 Takeda Chem Ind Ltd 20-acyloxy-20-demethylmaytansinoid compound
JPS55162791A (en) 1979-06-05 1980-12-18 Takeda Chem Ind Ltd Antibiotic c-15003pnd and its preparation
JPS5645483A (en) 1979-09-19 1981-04-25 Takeda Chem Ind Ltd C-15003phm and its preparation
EP0028683A1 (en) 1979-09-21 1981-05-20 Takeda Chemical Industries, Ltd. Antibiotic C-15003 PHO and production thereof
JPS5645485A (en) 1979-09-21 1981-04-25 Takeda Chem Ind Ltd Production of c-15003pnd
WO1982001188A1 (en) 1980-10-08 1982-04-15 Takeda Chemical Industries Ltd 4,5-deoxymaytansinoide compounds and process for preparing same
US4450254A (en) 1980-11-03 1984-05-22 Standard Oil Company Impact improvement of high nitrile resins
US4313946A (en) 1981-01-27 1982-02-02 The United States Of America As Represented By The Secretary Of Agriculture Chemotherapeutically active maytansinoids from Trewia nudiflora
US4315929A (en) 1981-01-27 1982-02-16 The United States Of America As Represented By The Secretary Of Agriculture Method of controlling the European corn borer with trewiasine
US4563304A (en) 1981-02-27 1986-01-07 Pharmacia Fine Chemicals Ab Pyridine compounds modifying proteins, polypeptides or polysaccharides
JPS57192389A (en) 1981-05-20 1982-11-26 Takeda Chem Ind Ltd Novel maytansinoid
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6100064A (en) 1984-04-06 2000-08-08 Chiron Corporation Secreted viral proteins useful for vaccines and diagnostics
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
CA2095633C (en) 1990-12-03 2003-02-04 Lisa J. Garrard Enrichment method for variant proteins with altered binding properties
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
EP0563475B1 (en) 1992-03-25 2000-05-31 Immunogen Inc Cell binding agent conjugates of derivatives of CC-1065
ES2176484T3 (es) 1995-08-18 2002-12-01 Morphosys Ag Bancos de proteinas/(poli)peptidos.
US7264963B1 (en) 1995-08-18 2007-09-04 Morphosys Ag Protein(poly)peptide libraries
EP1011694A4 (en) * 1996-11-15 2000-11-15 Baxter Int TREATMENT FOR ALLOGENIC STEM CELL TRANSPLANTATION
WO2001002588A2 (en) 1999-07-02 2001-01-11 Morphosys Ag Generation of specific binding partners binding to (poly)peptides encoded by genomic dna fragments or ests
US6333410B1 (en) 2000-08-18 2001-12-25 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
US20020151508A1 (en) * 2001-02-09 2002-10-17 Schering Corporation Methods for treating proliferative diseases
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
US6716821B2 (en) 2001-12-21 2004-04-06 Immunogen Inc. Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same
GB0202319D0 (en) 2002-02-01 2002-03-20 Calex Electronics Ltd Apparatus
WO2004082463A2 (en) * 2003-03-17 2004-09-30 Medical College Of Ohio Folate receptor gene modulation for cancer diagnosis and therapy
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
US7276497B2 (en) 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
CA2581208A1 (en) 2004-08-30 2006-03-09 Lonza Biologics Plc. Affinity- plus ion exchange- chromatography for purifying antibodies
ATE460668T1 (de) * 2005-03-30 2010-03-15 Purdue Research Foundation Verfahren zur prognose von brustkrebs mittels quantifizierung von zellulären folat vitamin rezeptoren
US20090162374A1 (en) * 2005-09-14 2009-06-25 Geraghty Daniel E Specific removal of activated immune cells
EP1900752A1 (en) * 2006-09-15 2008-03-19 DOMPE' pha.r.ma s.p.a. Human anti-folate receptor alpha antibodies and antibody fragments for the radioimmunotherapy of ovarian carcinoma
US7691980B2 (en) 2007-01-09 2010-04-06 Bio-Rad Laboratories, Inc. Enhanced capacity and purification of antibodies by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers
EP2238154B1 (en) 2008-01-18 2015-09-16 Bio-Rad Laboratories, Inc. Enhanced purification of phosphorylated and non-phosphorylated biomolecules by apatite chromatography
WO2009094456A2 (en) * 2008-01-22 2009-07-30 Johns Hopkins University Use of high-dose, post-transplantation oxazaphosphorine drugs for reduction of transplant rejection
SG189817A1 (en) 2008-04-30 2013-05-31 Immunogen Inc Potent conjugates and hydrophilic linkers
NZ610239A (en) 2008-04-30 2014-11-28 Immunogen Inc Cross-linkers and their uses
SI2378876T1 (sl) * 2008-12-19 2019-05-31 Medicis Pharmaceutical Corporation Formulacije z nižjo dozirno jakostjo imikvimoda in kratki odmerni režimi za zdravljenje aktinične keratoze
EP2490715A4 (en) * 2009-10-21 2013-06-26 Immunogen Inc NEW DOSAGE ADMINISTRATION REGIMEN AND METHOD OF TREATMENT
TWI622402B (zh) * 2010-02-24 2018-05-01 免疫遺傳股份有限公司 葉酸受體１抗體類和免疫共軛物類及彼等之用途
US8530122B2 (en) 2010-07-30 2013-09-10 Konica Minolta Business Technologies, Inc. Foil transferring face forming toner and image forming method
MX343607B (es) * 2010-11-05 2016-11-11 Morphotek Inc Receptor alfa de folato como marcador de diagnóstico y pronóstico para cánceres que expresan receptor alfa de folato.
BR112013025415B1 (pt) 2011-04-01 2021-03-16 Immunogen, Inc uso de um imunoconjugado antirreceptor de folato 1 (folr1)
WO2012138749A1 (en) 2011-04-04 2012-10-11 Immunogen, Inc. Methods for decreasing ocular toxicity of antibody drug conjugates
US9200073B2 (en) * 2012-08-31 2015-12-01 Immunogen, Inc. Diagnostic assays and kits for detection of folate receptor 1
NZ713868A (en) * 2013-04-08 2021-12-24 Berg Llc Treatment of cancer using coenzyme q10 combination therapies
SG11201509043RA (en) * 2013-05-14 2015-12-30 Immunogen Inc Anti-folr1 immunoconjugate dosing regimens
CN113150145B (zh) * 2013-08-30 2025-02-14 伊缪诺金公司 用于检测叶酸受体1的抗体和测定
CN116440279B (zh) * 2015-09-17 2026-02-24 伊缪诺金公司 包含抗folr1免疫缀合物的治疗组合

Also Published As

Publication number Publication date
IL298044B1 (en) 2024-07-01
UA119541C2 (uk) 2019-07-10
AU2020264270A1 (en) 2020-11-26
MX2016004411A (es) 2016-07-05
US20210155688A1 (en) 2021-05-27
SG11201602361UA (en) 2016-04-28
KR20220136468A (ko) 2022-10-07
ES2759426T3 (es) 2020-05-11
WO2015054400A2 (en) 2015-04-16
KR20200058592A (ko) 2020-05-27
KR102639861B1 (ko) 2024-02-22
HK1226671A1 (en) 2017-10-06
JP2024016239A (ja) 2024-02-06
JP2021178847A (ja) 2021-11-18
EP3055332A4 (en) 2017-05-31
KR102115217B9 (ko) 2021-12-24
JP2019218386A (ja) 2019-12-26
CN106164093A (zh) 2016-11-23
HRP20240917T1 (hr) 2024-10-11
EP4424323A2 (en) 2024-09-04
ES2983055T3 (es) 2024-10-21
AU2014331964B2 (en) 2018-09-13
PL3055332T3 (pl) 2020-02-28
PL3653228T3 (pl) 2024-11-12
HUE067367T2 (hu) 2024-10-28
RU2696579C2 (ru) 2019-08-05
MX384973B (es) 2025-03-14
US20150132323A1 (en) 2015-05-14
JP6463744B2 (ja) 2019-02-06
CA2926325C (en) 2023-08-01
SI3055332T1 (sl) 2020-02-28
LT3653228T (lt) 2024-07-25
CA2926325A1 (en) 2015-04-16
KR20210118220A (ko) 2021-09-29
RS65798B1 (sr) 2024-08-30
NZ718766A (en) 2020-02-28
SG10202102555TA (en) 2021-04-29
WO2015054400A3 (en) 2015-06-25
IL265586A (en) 2019-05-30
EP3055332B1 (en) 2019-09-25
AU2024201615A1 (en) 2024-04-04
SG10201907042PA (en) 2019-09-27
KR102303874B1 (ko) 2021-09-17
NZ757964A (en) 2022-07-01
KR20230145544A (ko) 2023-10-17
IL244772B (en) 2019-05-30
BR112016007479A2 (pt) 2017-09-12
PT3653228T (pt) 2024-07-17
EP3055332A2 (en) 2016-08-17
AU2020264270B2 (en) 2024-01-18
AU2018278880A1 (en) 2019-01-03
KR20160079797A (ko) 2016-07-06
CY1127391T1 (el) 2026-02-25
FI3653228T3 (fi) 2024-07-04
AU2014331964A1 (en) 2016-04-28
ZA201902009B (en) 2020-10-28
EP3653228B1 (en) 2024-05-15
DK3055332T3 (da) 2019-12-09
IL244772A0 (en) 2016-04-21
JP2019031568A (ja) 2019-02-28
RU2016114708A (ru) 2017-11-15
KR102115217B1 (ko) 2020-05-26
AU2014331964C1 (en) 2019-10-31
EP4424323A3 (en) 2024-11-13
IL313730A (en) 2024-08-01
MX2021009222A (es) 2021-09-08
PT3055332T (pt) 2019-12-09
KR20210041124A (ko) 2021-04-14
EP3653228A1 (en) 2020-05-20
DK3653228T3 (da) 2024-07-15
KR20240027861A (ko) 2024-03-04
SMT201900694T1 (it) 2020-01-14
MY174670A (en) 2020-05-06
IL298044B2 (en) 2024-11-01
US20240368270A1 (en) 2024-11-07
JP2016534039A (ja) 2016-11-04
LT3055332T (lt) 2020-04-10
JP7386208B2 (ja) 2023-11-24
SI3653228T1 (sl) 2024-09-30
HUE046696T2 (hu) 2020-03-30
HRP20192140T1 (hr) 2020-03-06
RU2016114708A3 (https=) 2018-07-31
JP6581279B2 (ja) 2019-09-25
IL298044A (en) 2023-01-01
RS59644B1 (sr) 2020-01-31

Similar Documents

Publication Publication Date Title
CY1122449T1 (el) Σχηματα δοσολογιας ανοσοσυζευγματος enanti-folr1
MX2015015735A (es) Regimenes de dosificacion de inmunoconjugado anti-receptor en folato 1 (folr1).
CY1125358T1 (el) Θεραπεια συνδυασμου η οποια περιλαμβανει εναν mdm2 αναστολεα και εναν ή περισσοτερους επιπροσθετους φαρμακευτικως δραστικους παραγοντες για την αντιμετωπιση καρκινων
CY1124298T1 (el) Φενφλουραμινη για χρηση στην θεραπευτικη αντιμετωπιση του συνδρομου dravet
CY1125436T1 (el) Αναστολεις dna-pk
CY1121735T1 (el) 7-benzyλ-10-(2-meθyλobenzyλ)-2,6,7,8,9,10-eξaϋδpoϊmiδazo[1,2-α]πυριδο[4,3-d]πυριμιδιν-5(3η)-ονη για χρηση στην αγωγη του καρκινου
CY1122671T1 (el) Θεραπευτικως δραστικες ενωσεις και οι μεθοδοι χρησεις αυτων
CY1122490T1 (el) Αντισωματα κατα του ανθρωπινου cd38
CY1120506T1 (el) Θεραπευτικα δραστικες ενωσεις και μεθοδοι χρησης αυτων
EA201691059A1 (ru) Соединения-пептидомиметики и содержащие их конъюгаты антитело-лекарственное средство
EA201691023A1 (ru) Пептидомиметические соединения и их конъюгаты антитела с лекарственным средством
CY1120730T1 (el) Απο του στοματος χορηγουμενη δοσολογια ενωσεων glp-1
EA201592107A1 (ru) Доставка иммунодепрессантов, имеющих определенный фармакодинамически эффективный период, и антигена для индукции иммунной толерантности
EA201890272A1 (ru) Axl-специфические конъюгаты антитело-лекарственное средство для лечения рака
PH12016501995A1 (en) Tubulysin derivatives
EA201792300A1 (ru) Комбинации иммуноконъюгата к cd37 и антитела к cd20
MX340090B (es) Analogos de spliceostatina.
EA202092967A1 (ru) Схемы приема иммуноконъюгата антитела против cd37
CY1123982T1 (el) Θεραπευτικη αγωγη για το πολλαπλο μυελωμα (μμ)
EA201590359A1 (ru) Лечение ревматоидного артрита
WO2015175533A3 (en) Anti-cd37 immunoconjugate dosing regimens
CY1124543T1 (el) Τμηματα χορηγησης δοσολογησης ανοσοθεραπευτικων που περιλαμβανουν πομαλιδομιδιο και αντισωμα anti-cs1 για αγωγη καρκινου
WO2020092533A3 (en) Methods of treatment using anti-cd123 immunoconjugates
MX2018005097A (es) Anticuerpos altamente potentes que se unen a receptor de muerte 4 y receptor de muerte 5.
MY203104A (en) Anti-folr1 immunoconjugate dosing regimens